Cargando…

Cancer Vaccines in Ovarian Cancer: How Can We Improve?

Epithelial ovarian cancer (EOC) is one important cause of gynecologic cancer-related death. Currently, the mainstay of ovarian cancer treatment consists of cytoreductive surgery and platinum-based chemotherapy (introduced 30 years ago) but, as the disease is usually diagnosed at an advanced stage, i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Martin Lluesma, Silvia, Wolfer, Anita, Harari, Alexandre, Kandalaft, Lana E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5344251/ https://www.ncbi.nlm.nih.gov/pubmed/28536377 http://dx.doi.org/10.3390/biomedicines4020010

Ejemplares similares

Vaccines as Priming Tools for T Cell Therapy for Epithelial Cancers
por: Kandalaft, Lana E., et al.
Publicado: (2021)

Does the Immunocompetent Status of Cancer Patients Have an Impact on Therapeutic DC Vaccination Strategies?
por: Martin Lluesma, Silvia, et al.
Publicado: (2018)

Emerging Opportunities of Radiotherapy Combined With Immunotherapy in the Era of Breast Cancer Heterogeneity
por: Tsoutsou, Pelagia G., et al.
Publicado: (2018)

A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma
por: Sarivalasis, Apostolos, et al.
Publicado: (2019)

Integrating Cancer Vaccines in the Standard-of-Care of Ovarian Cancer: Translating Preclinical Models to Human
por: Chiang, Cheryl Lai-Lai, et al.
Publicado: (2021)

Whole Tumor Antigen Vaccines: Where Are We?
por: Chiang, Cheryl Lai-Lai, et al.
Publicado: (2015)

Deciphering the Mechanisms of Improved Immunogenicity of Hypochlorous Acid-Treated Antigens in Anti-Cancer Dendritic Cell-Based Vaccines
por: Graciotti, Michele, et al.
Publicado: (2020)

IL-15 and a Two-Step Maturation Process Improve Bone Marrow-Derived Dendritic Cell Cancer Vaccine
por: Mookerjee, Ananda, et al.
Publicado: (2019)

Longitudinal analysis of DC subsets in patients with ovarian cancer: Implications for immunotherapy
por: Mastelic-Gavillet, Beatris, et al.
Publicado: (2023)

Autologous whole-tumor antigen vaccination in combination with adoptive T cell therapy for patients with recurrent ovarian cancer
por: Kandalaft, Lana E, et al.
Publicado: (2013)

The era of bioengineering: how will this affect the next generation of cancer immunotherapy?
por: Graciotti, Michele, et al.
Publicado: (2017)

A Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer
por: Kandalaft, Lana E, et al.
Publicado: (2013)

Personalized cancer vaccine strategy elicits polyfunctional T cells and demonstrates clinical benefits in ovarian cancer
por: Tanyi, Janos L., et al.
Publicado: (2021)

A phase I clinical trial of adoptive transfer of folate receptor-alpha redirected autologous T cells for recurrent ovarian cancer
por: Kandalaft, Lana E, et al.
Publicado: (2012)

A Phase Ib Study of the Combination of Personalized Autologous Dendritic Cell Vaccine, Aspirin, and Standard of Care Adjuvant Chemotherapy Followed by Nivolumab for Resected Pancreatic Adenocarcinoma—A Proof of Antigen Discovery Feasibility in Three Patients
por: Bassani-Sternberg, Michal, et al.
Publicado: (2019)

A cancer vaccine with dendritic cells differentiated with GM-CSF and IFNα and pulsed with a squaric acid treated cell lysate improves T cell priming and tumor growth control in a mouse model
por: Mookerjee, Ananda, et al.
Publicado: (2018)

Correction: A cancer vaccine with dendritic cells differentiated with GM-CSF and IFNα and pulsed with a squaric acid treated cell lysate improves T cell priming and tumor growth control in a mouse model
por: Mookerjee, Ananda, et al.
Publicado: (2019)

Author Correction: Personalized cancer vaccine strategy elicits polyfunctional T cells and demonstrates clinical benefits in ovarian cancer
por: Tanyi, Janos L., et al.
Publicado: (2021)

Development and Optimization of a GMP-Compliant Manufacturing Process for a Personalized Tumor Lysate Dendritic Cell Vaccine
por: Boudousquié, Caroline, et al.
Publicado: (2020)

How Mandatory Can We Make Vaccination?
por: Saunders, Ben
Publicado: (2022)

How We Will, Not Whether We Can: Improving Health and Healthcare
por: Zelmer, Jennifer
Publicado: (2017)

Cancer vaccines based on whole-tumor lysate or neoepitopes with validated HLA binding outperform those with predicted HLA-binding affinity
por: Fritah, Hajer, et al.
Publicado: (2023)

Locally Performed HRD Testing for Ovarian Cancer? Yes, We Can!
por: Magliacane, Gilda, et al.
Publicado: (2022)

How can we improve the interpretation of systematic reviews?
por: Tricco, Andrea C, et al.
Publicado: (2011)

How Can We Treat Cancer Disease Not Cancer Cells?
por: Kim, Kyu-Won, et al.
Publicado: (2017)

TEM1-targeting PEGylated PLGA shikonin nanoformulation for immunomodulation and eradication of ovarian cancer
por: Matthaiou, Efthymia-Iliana, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors in Cancer Therapy—How Can We Improve Clinical Benefits?
por: Baxevanis, Constantin N.
Publicado: (2023)

How can we improve amniocentesis decision-making?
por: Lehmann, Lisa Soleymani
Publicado: (2016)

How can we recognize continuous quality improvement?
por: Rubenstein, Lisa, et al.
Publicado: (2014)

3. How comprehensive can we be in the economic assessment of vaccines?
por: Standaert, Baudouin, et al.
Publicado: (2017)

Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer
por: Kandalaft, Lana E., et al.
Publicado: (2013)

Operative and Pathological Factors in Right-Sided Colon Cancers: How Can We Improve the Outcomes?
por: Conroy, Soraya F, et al.
Publicado: (2023)

Gastric Cancer: How Can We Reduce the Incidence of this Disease?
por: den Hoed, Caroline M., et al.
Publicado: (2016)

Anaplastic thyroid cancer: How far can we go?
por: Amaral, Mariana, et al.
Publicado: (2020)

Tackling cisplatin resistance in ovarian cancer: what can we do?
por: Perego, Paola
Publicado: (2021)

Detecting ovarian cancer in primary care: can we do better?
por: Funston, Garth, et al.
Publicado: (2022)

Spinal anesthesia: how can we improve patient satisfaction?
por: Lee, Jong Seok
Publicado: (2010)

How Can We Improve Disease Education in People with Gout?
por: Fields, Theodore R., et al.
Publicado: (2018)

Bronchopulmonary dysplasia: how can we improve its outcomes?
por: Sung, Tae-Jung
Publicado: (2019)

Coronary surgery in women: How can we improve outcomes
por: Zwischenberger, Brittany A., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_n3li2fnhg96u9sflk75e6oenp7